Aeolus Pharmaceuticals Inc · OTC:AOLS

Aeolus Pharmaceuticals — Investor Presentation (January 2013)

31 slides from Aeolus Pharmaceuticals's investor presentation, January 2013

  1. Slide 1: Protecting Healthy Tissue – Aeolus Pharmaceuticals, January 2013

    Leveraging government funding to develop a platform of broad‐spectrum, catalytic‐antioxidant compounds for bio‐defense, cancer and neurology John McManus President & Chief Executive Officer Russell Skibsted Senior Vice President & Chief Financial Officer Protecting Healthy Tissue January 2013

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward‐looking statements regarding future events and the future performance of Aeolus Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statemen

  3. Slide 3: Novel Platform

    Novel Platform Mechanism of Action Protects healthy cells surrounding tumor from radiation damage – could allow for higher radiation dosing Enhances tumor control through regulation of the PTEN pathway Medical countermeasure (>$150M in funding) Lung‐ARS Chlorine Gas GI‐ARS Mustard Gas Nerve A

  4. Slide 4: Leveraging Non-Dilutive Funding

    Leveraging Non‐Dilutive Funding BARDA (Lung ARS) $118M >$2M NIAID/DAIT (GI ARS Mouse & NHP) CounterACT (Chlorine & Sulfur Mustard Gas) $12.7M CounterACT (Nerve Agents) More than $1M $150 $1M NIH/NIAID (Phosgene) Million NIH/NIAID (ARS – AEOL 10171) $20M Michael J. Fox/IRS (Parkinson’s AEOL 11207) $0

  5. Slide 5: Key Accomplishments

    Key Accomplishments • Completed 2nd Year of $118 million, 5 Year contract with US Government (BARDA) – Added 18 additional deliverables from cost savings in first two years – BARDA exercised $9.1 million in 2nd Year options • Received FDA concurrence on animal model developed for two species (NHP &

  6. Slide 6: Medical Countermeasure Program

    Medical Countermeasure Program Protecting Healthy Tissue

  7. Slide 7: Acute Radiation Syndrome

    Acute Radiation Syndrome 2-6 Dr. Tom MacVittie (courtesy of Fred Mettler) 7

  8. Slide 8: BARDA Lung ARS Contract

    BARDA Lung ARS Contract • Awarded February 11, 2011 • $118 million in potential revenue over 5 years • Cost‐plus contract (covers costs & significant overhead) • Emergency Use Authorization • Fully funds AEOL 10150 to FDA approval • Base contract and 2 options exercised total $19.5 million (period o

  9. Slide 9: BARDA Lung ARS Contract

    BARDA Lung ARS Contract Pre‐IND Orphan IND/Fast Track Phase 1 Human Safety Study Meeting Drug Filing Filing NHP Radiation Dose Study NHP Radiation Dose Amendment NHP 10150 Dose Evaluation CBA Radiation Dose CBA Rad Dose Amendment CBA 10150 Dose Escalation Add‐on CBA 10150 Dose Escalation Murine (CBA

  10. Slide 10: Project Team

    Project Team David Cavalier – Chairman University of Maryland (NHP) Tom MacVittie, PhD John McManus – President & CEO Michael Garofalo, MD Russell Skibsted – Sr. VP & CFO Ann Farese, MSc Brian Day, PhD – Chief Scientific Officer University of Maryland (Murine) Zeljko Vujaskovic, MD, PhD Richard Stea

  11. Slide 11: Achievements in Base Year

    Achievements in Base Year • Built Development Team • Animal Model Development and Efficacy – NHP Model – developed and validated – Murine Models – CBA & C57LJ – developed and validated – Two Drug Dose Escalation Studies underway • Chemistry, Manufacturing & Controls – Manufactured non‐GMP & GMP lots

  12. Slide 12: BARDA Lung ARS Contract: Expected Timeline to Emergency Use Authorization

    BARDA Lung ARS Contract Expected Timeline to Emergency Use Authorization Orphan IND Fast Emergency Drug Filing Track Use Filing Status Authorization Human Safety Studies NHP Radiation Dose Study NHP 10150 Dose Escalation Murine C57LJ 10150 Dose Escalation Radiation Dose CBA 10150 Dose Escalation CBA

  13. Slide 13: Lung ARS Survival Data

    Lung ARS Survival Data 15 Gy Exposure – 90% Survival; C57BL6 mice exposed to 15 Gy upper‐body irradiation and treated 2 hours post‐exposure with AEOL 10150 Source: Zeljko Vujaskovic, MD, PhD – Duke University 13

  14. Slide 14: Lung ARS Efficacy Data

    Lung ARS Efficacy Data Benefits GI Syndrome C57BL6 Mice Exposed to 15 Gy upper-body irradiation and treated 2 hours post-exposure with AEOL-10150.

  15. Slide 15: Lung Duration of Treatment Data

    Lung Duration of Treatment Data 12.5 Gy Upper Half Body (UHBI) 8 * 7 • Subcutaneous * * injection 6 * • 40 mg/kg Lung Damage Score 5 loading dose – 4 24 hours post irradiation 3 • Maintenance 2 dose of 20 1 mg/kg given every other day 0 Zeljko Vujaskovic, MD, PhD; Zahid Rabini, PhD; Lauren Jackson –

  16. Slide 16: Lung ARS NHP Survival Data

    Lung ARS NHP Survival Data • 11.5 Gy WTLI exposure in Rhesus Macaques(>LD99/180) – AEOL 10150 administered 24 hours after exposure for 28 days • Survival: – None of the six control animals survived, – 2 of the 7 (or 28.5%) of the animals receiving AOLS 10150 survived • Secondary endpoints: – Organ D

  17. Slide 17: ARS Threat/Procurement Need

    ARS Threat/Procurement Need Terrorism: “Several hundred thousand people may be at risk following a 10 KT nuclear explosion where effective planning and response actions could save many of them.” Planning Guidance for Response to a Nuclear Detonation, Homeland Security Council Interagency Policy Coor

  18. Slide 18: Summary of AEOL 10150 Studies

    Summary of AEOL 10150 Studies • Lung ‐ Acute Radiation Syndrome (University of Maryland/Duke/Indiana) – Radiation Dose Evaluation (mouse) – BARDA ‐ Completed – Radiation Dose Evaluation (NHP) – BARDA ‐ Completed – 10150 Dose Escalation (CBA mouse) ‐ BARDA – Completed – 10150/Neupogen Combination (mo

  19. Slide 19: Summary of AEOL 10150 Studies

    Summary of AEOL 10150 Studies • Chlorine Gas – Lung (National Jewish Health) – Confirmatory Rat Efficacy Study – NIH CounterACT ‐ Completed – Rat Dose Escalation Study – NIH CounterACT ‐ Underway • Sulfur Mustard Gas – Lung (US Army Institute of Chemical Defense) – Rat Efficacy ‐ Higher/Longer Expos

  20. Slide 20: Oncology Program

    Oncology Program AEOL 10150 Protecting Healthy Tissue

  21. Slide 21: Initial Indication – Lung Cancer

    Initial Indication – Lung Cancer • Non‐small cell lung cancer (NSCLC) • Radiation therapy causes damage to: – Lung tissue: breathing difficulty, pneumonitis, fibrosis – Esophagus: esophagitis, weight loss, difficulty swallowing • Side effects are RT‐dose limiting factor • Program leverages off of BA

  22. Slide 22: Radiation Effects in Lung

    Radiation Effects in Lung Free Radicals TGFB1 es oo DNA Damage Cell Death Fibrosis Inflammation Vascular Dysfunction "yal Tissue Destruction [Ne 22

  23. Slide 23: Preclinical Data in NSCLC

    Preclinical Data in NSCLC AEOL 10150 did not interfere with lung tumor kill when administered with radiation and/or chemo, but provided increased tumor control as a third agent 3000 Ctl A Mice were implanted with P human NSCLC tumors and A+P 2500 RT treated with all potential RT + A combinations of

  24. Slide 24: Upcoming Milestones

    Upcoming Milestones • 800 mouse efficacy study • GMP plant batch of API and final product • Non‐human primate dose escalation study • Mechanism of action study • Filing of IND for Lung ARS/DEARE • Phase I human clinical safety study • 300 mouse duration of treatment study 24

  25. Slide 25: Unique Value Proposition

    Unique Value Proposition Added potential for procurement order(s) >$150 million in Advancing non‐dilutive oncology funding over 5‐ programs years Shareholder Value 25

  26. Slide 26: Thank You

    Thank You INVESTOR AND MEDIA CONTACT Russell Skibsted Tel: (949) 481-9821 Email: info@aolsrx.com Protecting Healthy Tissue

  27. Slide 27: BARDA Deliverables/Milestones

    BARDA Deliverables/Milestones Completed Due by Hire Radiation Biologist  Hire Director Quality Assurance  Sign Quality Agreements  Submit Risk Management Plan  Submit Earned Value Mgmt Plan  Complete Murine Radiation Dose Study  Initial Non‐GMP Batch Production  Achieve Significant Improvemen

  28. Slide 28: BARDA Deliverables/Milestones

    BARDA Deliverables/Milestones Completed Due by Complete Final Product Process Development Work  Hold 2nd Pre‐IND Meeting with FDA  Initiate NHP AEOL 10150 Dose Evaluation Study  Complete Final Drug Product Formulation Development  Complete Murine Radiation Dose Study Amendment (C57LJ)  Initiate

  29. Slide 29: AEOL 10150 – Acute Radiation Syndrome

    AEOL 10150 – Acute Radiation Syndrome Benefits Lung Syndrome C57BL6 Mice Exposed to 15 Gy upper-body irradiation and treated 2 hours post-exposure with AEOL-10150. ( P<0.05).

  30. Slide 30: AEOL 10150 – Reduces Inflammation

    AEOL 10150 – Acute Radiation Syndrome Reduces Inflammation Nitrotyrosine 50 *+ p<0.05 45 +* 40 Relative Expression (%age) 35 30 25 * * 20 15 + 10 5 0 control RT RT+20mg RT+40mg 20mg 40mg Zeljko Vujaskovic, MD, PhD – Duke University

  31. Slide 31: AEOL 10150 – Reduces Oxidative Stress

    AEOL 10150 – Acute Radiation Syndrome Reduces Oxidative Stress 8 OHdG *+ p<0.05 70 Relative nuclear staining 8OHdG (%age 60 +* 50 40 * 30 * 20 + 10 0 control RT RT+20mg RT+40mg 20mg 40mg Zeljko Vujaskovic, MD, PhD – Duke University

Aeolus Pharmaceuticals — Investor Presentation (January 2013) on 6ix